The GLP-1 revolution, which started with relatively modest single-agonist drugs, has progressed to dual-agonists, then triple-agonists, and the pipeline continues to expand
Four forces shaped what he was watching: The most profitable book was disappearing
Based on these results, semaglutide is expected to be submitted to FDA for MASH in 2025, potentially becoming the first GLP-1 RA officially approved for MASH
If the math is wrong, it gets caught before the vial is touched
By connecting prescription therapy with evidence-based behavior change and daily support, Noom helps people not only lose weight but maintain their results long after treatment ends
Injection logging Keep a simple log of each injection: date, time, site location, dose, and any notes about your experience